ADA-friendly PDF: Treatment Guidelines: Use of Low-Dose Tamoxifen in Patients with Estrogen Receptor-Positive (ER+) Ductal Carcinoma in Situ (DCIS)

Use of Low-Dose Tamoxifen in Patients with Estrogen Receptor-Positive (ER+) Ductal Carcinoma in Situ (DCIS)

Back to Symposium

The Breast Oncology Center at Dana-Farber Brigham Cancer Center held a multidisciplinary meeting on May 12, 2023 to discuss recommendations for the use of low-dose tamoxifen in patients with Ductal Carcinoma in Situ (DCIS).